1 Result: NYSEMKT:CRMD
CorMedix Inc. Reports Update on Neutrolin(R) Phase 3 LOCK-IT 100 Clinical Trial
April 20th, 2017
Bedminster, NJ / CRWE PRESS RELEASE / April 20, 2017 - CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease,. Read more
Want To Find Some News?
News By Industries
April 29th, 2017April 28th, 2017April 27th, 2017